anonymous
Guest
anonymous
Guest
Didn't we learn from Novartis that if you give it all away you don't actually book revenue?
Our help with co-pays is just too much. The patient needs to pay something for 2 years of therapy!
Also, we need to open up the distribution channel. Diplomat can't get it done. They won't even do a 2nd line appeal. BioPlus is no better.
Our help with co-pays is just too much. The patient needs to pay something for 2 years of therapy!
Also, we need to open up the distribution channel. Diplomat can't get it done. They won't even do a 2nd line appeal. BioPlus is no better.